This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
the number of infants vaccinated against BCG in 1996; the proportion of vaccinated infants; the proportion of purified protein derivative (PPD) positive infants; the TB incidence among the cohort in Japan for two age groups, 0 to 4 years and 5 to 9 years; the hypothetical incidence of TB among the unvaccinated; and the hypothetical incidence of TB among the vaccinated.
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Not reported. The authors reported that they mainly used published reports of meta-analyses of data.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The estimates for the input parameters to the model were derived from 7 published studies.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The results of the outcomes used as input parameters to the model were as follows: the vaccine efficacy against TB was 40 to 80%; the vaccine efficacy against TB-meningitis was 64 to 86%; the duration of the BCG vaccine's effectiveness was 10 years; the number of infants born in Japan in 1996 was 1.2 million; the number of infants vaccinated against BCG in 1996 was 1.15 million; the proportion of vaccinated infants was 0.955;
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Measure of benefits used in the economic analysis
The measure of benefit used in the economic analysis was the number of TB cases avoided.
Direct costs
The analysis included the costs of a vaccination programme. These were derived from actual expenditure data on the BCG vaccination programme in Kyoto. The cost of the programme included the costs of the PPD testing kit, the BCG vaccines, the injection materials and the personnel. The costs of treating side effects of BCG vaccination and follow-up of PPD positive cases were also included. These were derived from published reports and expert opinion. The costs were discounted at a rate of 5%. The price year was not reported.
Statistical analysis of costs
No statistical analysis of the costs was conducted.
Indirect Costs
No indirect costs were included in the analysis.
Currency
US dollars ($). The exchange rate was Yen 110 = $1.
Sensitivity analysis
A series of one-way sensitivity analyses were performed in order to test the robustness of the results. The parameters varied were the duration of BCG protection, TB incidence, vaccine coverage and the discount rate.
Estimated benefits used in the economic analysis
The total number of TB cases averted was 111 for a vaccine efficacy rate of 40%, 228 for a vaccine efficacy rate of 60%, and 542 for a vaccine efficacy rate of 80%.
Cost results
The authors reported that the total cost associated with the vaccination programme was $19.5 million. This does not appear to include the cost of treating children with TB infection. The costs associated with no vaccination were not reported.
Synthesis of costs and benefits
The costs and the benefits were synthesised by dividing the costs of the vaccination by the number of TB cases averted. This equates to an incremental cost-effectiveness ratio if it is assumed that the costs of the no vaccination programme are zero.
The cost per TB case averted was $175,682 for a vaccine efficacy rate of 40%, $85,348 for a vaccine efficacy rate of 60%, and $35,950 for a vaccine efficacy rate of 80%.
